BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. · 2007

Read BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. by Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2043012.txt.

Introduction

Costa and co-workers identified in 2007 a protein that drives drug-induced death in lung cancer cells. Some lung cancers carry mutations in the EGFR gene and respond to drugs called tyrosine kinase inhibitors, such as gefitinib. Most later resist treatment, often through a second mutation named T790M. The team studied sensitive and resistant cancer cell lines and a tumour sample from a resistant patient.

A pro-death protein called BIM rose in sensitive cells when gefitinib was given, and cell death followed. The T790M mutation blocked both the BIM rise and the death. An irreversible drug overcame that block. Silencing BIM reduced drug-induced death directly. A new resistance mutation, L747S, was found in the patient's tumour. It also weakened the BIM response.

Catalog record

CREATORCosta DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2043012

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations By Daniel B Costa, Balázs Halmos, Amit Kumar, Susan T Schumer, Mark S Huberman, Titus J Boggon, Daniel G Tenen, Susumu Kobayashi, Ingo K Mellinghoff Published in: PLoS Medicine DOI: 10.1371/journal.pmed.0040315 ABSTRACT Abstract Background Epidermal growth factor receptor (EGFR) mutations are present in the majority of patients with non-small cell lung cancer (NSCLC) responsive to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. These EGFR-dependent tumors eventually become TKI resistant, and the common secondary T790M mutation accounts for half the tumors with acquired resistance to gefitinib. However, the key proapoptotic proteins involved in TKI-induced cell death and other secondary mutations involved in resistance remain unclear. The objective of this study was to identify the mechanism of EGFR TKI-induced apoptosis and secondary resistant mutations that affect this process. Methods and Findings To study TKI-induced cell death and mechanisms of resistance, we used lung cancer cell lines (with or without EGFR mutations), Ba/F3 cells stably transfected with EGFR mutation constructs, and tumor samples from a gefitinib-resistant patient. Here we show that up-regulation of the BH3-only polypeptide BIM (also known as BCL2-like 11) correlated with gefitinib-induced apoptosis in gefitinib-sensitive EGFR-mutant lung cancer cells. The T790M mutation blocked gefitinib-induced up-regulation of BIM and apoptosis. This blockade was overcome by the irreversible TKI CL-387,785. Knockdown of BIM by small interfering RNA was able to attenuate apoptosis induced by EGFR TKIs. Furthermore, from a gefitinib-resistant patient carrying the activating L858R mutation, we identified a novel secondary resistant mutation, L747S in cis to the activating mutation, which attenuated the up-regulation of BIM and reduced apoptosis. Conclusions Our results provide evidence that BIM is involved in TKI-induced apoptosis in sensitive EGFR-mutant cells and that both attenuation of the up-regulation of BIM and resistance to gefitinib-induced apoptosis are seen in models that contain the common EGFR T790M and the novel L747S secondary resistance mutations. These findings also suggest that induction of BIM may have a role in the treatment of TKI-resistant tumors. INTRODUCTION Sequencing of the epidermal growth factor receptor (EGFR) gene in a large number of tumor samples has identified somatic activating mutations in the tyrosine-kinase pocket of EGFR [1,2]. These mutations were first described in non-small cell lung cancer (NSCLC) patients treated with specific EGFR tyrosine kinase inhibitors (TKIs)—gefitinib and erlotinib—who had radiographic and clinical responses to such agents [3–5]. Two recent transgenic mouse models, in which the overexpression of EGFR mutations was targeted in type II pneumocytes, demonstrated that these mutations led to the development of adenocarcinomas and that the tumors responded both to suppression of the EGFR driving signal and EGFR TKIs [6,7]. As data accumulate, it seems clear that EGFR-mutant “oncogene-addicted” cancers represent a distinct form of NSCLC that can be targeted through novel approaches [8]. The tumor cells are dependent on, or addicted to, the EGFR mutated oncogene for both maintenance of the malignant phenotype and cell survival. At the time of this writing, phase II trials in which patients with advanced NSCLC are included on the basis of presence of the two most common EGFR mutations (either exon 19 deletions or the exon 21 arginine-for-leucine substitution at amino acid 858, or L858R) and are given gefitinib as first-line treatment show radiographic response rates that exceed 75% [9–11]. Mature results of such trials will likely confirm the improved time to progression and survival seen in retrospective studies of patients treated with TKIs in which EGFR mutations had been identified [12–15]. Despite the unprecedented responses seen in these specific EGFR-mutant tumors, most eventually become resistant to the TKIs and disease progression is noted. Our group and others have identified a second mutation in the EGFR kinase domain (the exon 20 methionine to threonine substitution at position 790, or T790M) in repeat tissue samples from patients who initially responded to TKIs but later progressed [16,17]. The two largest cohorts of patients with TKI-resistant NSCLCs, in which a second biopsy was obtained after progression, identified the T790M mutation in around 50% of the samples and one D761 secondary mutation [18,19]. Recently, in four out of 18 (22%) TKI-resistant EGFR-mutant tumors, amplification of another oncogene, MET, was identified [20]. Other secondary mutations and alternative mechanisms of resistance have not been completely clarified. One of the major effects of TKIs in sensitive EGFR-mutant cell lines is their induction of apoptosis. The exquisite sensitivity of these NSCLCs to gefitinib and erlotinib [3–5] has been supported by the concept of “oncogene addiction” [6,7,21]. A recent report suggested that a common signaling cascade may be involved during apoptosis in cells that depend on oncogenic SRC, BCR-ABL, and mutant EGFR [22]. Interestingly, the BH3-only proapoptotic proteins BIM (also referred to as BCL2-like 11, or BCL2L11), and to a lesser extent BAD (BCL2 antagonist of cell death), mediate imatinib-induced apoptosis of BCR-ABL leukemic cells [23]. The key downstream mediators of TKI-induced cell death in EGFR-mutant tumors remain unknown. We hypothesized that the BH3-only members might be involved in the apoptotic signal following EGFR disruption by TKIs. In this study we studied BIM's role in TKI-induced apoptosis in EGFR-mutant lung cancers. In addition, we investigated the effect of the resistant mutation T790M and a novel secondary mutation, L747S, on the regulation of BIM and apoptosis. METHODS Patient Characteristics and Clinical Course after TKI Treatment Two EGFR mutation-positive patients with gefitinib-resistant NSCLCs and secondary EGFR mutations were identified from our Thoracic Oncology Clinic database. Their clinical and molecular characteristics, as well as their response to TKI treatment, are detailed in Table S1. Both patients are part of an Institutional Review Board-approved protocol, and written informed consent was obtained for the analysis of their tumors. Reagents Gefitinib and erlotinib were purchased from a commercial supplier. CL-387,785 was purchased from Calbiochem (Darmstadt, Germany). Stock solutions for gefitinib, erlotinib, and CL-387,785 were prepared as previously described [16]. Sequencing of the EGFR Gene Both genomic DNA and total RNA were extracted from the tumor cells of a transbronchial biopsy and of pleural fluid in patients 1 and 2 (Table S1), respectively. Genomic DNA was used as a template for sequencing exons 18–21 as previously published [3]. cDNA was transcribed from 1 μg of total RNA with Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA). The cDNA was used as a template for subsequent PCR amplifications of EGFR. The kinase domain of the EGFR coding region was amplified by the use of two sets of oligonucleotides and sequenced: (1) sense primer (5′-GCA CAG GAC GGG GAC CAG ACA ACT-3′) and antisense primer (5′-GGA CAT AGT CCA GGA GGC AG-3′); (2) sense primer (5′-GCA CAG GAC GGG GAC CAG ACA ACT-3′) and antisense primer (5′-ATG GGT GGC TGA GGG AGG CGT TCT-3′). The PCR products containing exons 19–21 amplified by the use of the latter set of primers were subcloned into the pGEM-T Easy cloning vector (Invitrogen) and sequenced [16]. Cell Culture Ba/F3 cell lines were maintained in RPMI supplemented with 10% FBS and 5% WEHI conditioned medium as the source of IL3. The human lung cancer-derived cells lines A549, NCI-H460 (H460), NCI-H1975 (H1975), NCI-H3255 (H3255), PC-9, and HCC827 were maintained in RPMI supplemented with 10% FBS. EGFR Mutant Constructs and Transfections The L747S mutation was introduced

Read the complete text